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132-microglobulin associated amyloidosis: A vanishing complication of
long-term hemodialysis? 2-microglobulin associated amyloidosis (A2m
amyloidosis) is considered an inevitable complication of chronic hemodi-
alysis, particularly in hemodialysis with cellulose based membranes. We
performed a single center study to assess the prevalence of AI32m
amyloidosis in 1988 versus 1996. Randomly selected patients, studied in
1988, were matched for time on hemodialysis (mean 71 months, range 3 to
207) and age (mean 51 years, range 22 to 80) with patients of the 1996
population. Compared to 1988 patients, the 1996 patients exhibited a
lower prevalence of carpal tunnel syndrome (7 of 43 in 1988 vs. 1 of 43 in
1996; P < 0.001) and radiological evidence of A132m amyloidosis (13 of 34
patients vs. 3 of 34 patients positive; P < 0.001; and 33 of 272 possible sites
affected in 1988 vs. 7 of 272 sites in 1996 patients; P < 0.05). Compared to
the 1988 population, the 1996 population exhibited significantly lower
serum aluminum levels, lower average serum creatinine (but not urea)
levels, more frequent therapy with erythropoietin, less home hemodialysis,
longer hemodialysis time using high-flux synthetic dialysis membranes(mean of 13% vs. 6% of the total hemodialysis time in the 1988 group),
and more frequent usage of reverse osmosis water plus bicarbonate buffer
for dialysate preparation. We conclude that the prevalence and severity of
A132m amyloidosis unexpectedly decreased by about 80% in our center
between 1988 and 1996. Given the relatively short times spent on high flux
hemodialysis in both groups, increased 2-microglobulin removal is un-
likely to account for this phenomenon. Rather, other factors, for example,
dialysate composition and purity, may be involved.
Beta-2-microglobulin associated amyloidosis (AJ32m amyloid-
osis), also known as dialysis-related amyloidosis, is a serious
complication of long-term dialysis treatment [1, 2]. The pathogen-
esis of the disease is related to retention of the amyloid precursor
protein, 2-microglobulin, in renal failure [1, 2]. Further, local
factors in the synovial tissue also appear to contribute to the
pathogenesis of Ap7m amyloidosis, since clinical symptomatology
is largely confined to the musculoskeletal system, in particular
large joints [1, 2]. Data obtained during the 1980s suggested that
the disease may be an inevitable complication of long-term
dialysis, since in several studies the prevalence of the amyloidosis
approached 100% in patients treated for more than 15 years
[3—61. However, in these latter studies, all patients had been
hemodialyzed with 2-microglobulin impermeable dialyzers. Var-
ious groups have therefore addressed the question of whether
high-flux membranes, which do permit significant f32-micro-
globulin removal, might influence the prevalence of AJ32m
amyloidosis. While the results of these studies are not uniform
[reviewed in 7, 8], the largest and best controlled of them
suggested that therapy with high-flux synthetic membranes may
delay the appearance of clinical signs of A2m amyloidosis, in
particular "cystic" bone radiolucencies, that is, amyloid depos-
its in the bone [9].
Based on the above observations, we have addressed two
questions in the present study: First, has the prevalence of Af32m
amyloidosis changed between the 1980s and 1990s? Second, can a
change of the prevalence be related to the more widespread usage
of high flux membranes for hemodialysis? To answer these two
questions, we performed a single center study on the prevalence
of A/32m amyloidosis in a randomly selected group of hemodial-
ysis patients who were studied in 1988, and a group of patients
studied in 1996. Patients of the 1996 group were matched with
those of the ii 988 group for the only two factors, which have been
unequivocally identified as affecting the prevalence of A132m
amyloidosis: patient age and time on hemodialysis [1, 2, 9].
METHODS
Patients
In 1988 we had performed a systematic study on X-ray findings
in all hemodialysis patients treated chronically at the Mcdi-
zinische Hochschule Hannover [10]. A total of 112 patients was
studied. These X-ray pictures (see below) as well as clinical
findings retrospectively available from the patients files formed
the basis of the present study. The 112 patients of the 1988 group
were matched for age and time on hemodialysis with 127 patients
of the current, 1996, hemodialysis population. Match criteria
were: age in years 6 years; time on chronic hemodialysis
treatment (except for times with a functioning renal transplant)
6 months.
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Clinical data. In all patients age, sex, underlying renal disease,
times with functioning renal transplants, and parathyroidectomies
were recorded. Residual diuresis was classified at the time of the
study as either < 100 mI/day, 100 to 500 mI/day, 500 to 1000
mi/day or > 1000 mi/day. Carpal tunnel syndrome was diagnosed
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on the basis of typical complaints, electrophysiologic findings plus
the need for operative dissection of the carpal ligament.
Radiological data. In all patients who consented to X-ray
evaluation, anterior-posterior images of the hands, shoulders,
pelvis including hips and knees were obtained. All X-rays were
read by one or two radiologists, who were unaware of clinical
details of the patients. X-ray images were considered to he
indicative of the presence of A32m amyloidosis if the following
criteria, modified from those used previously by van Ypersele et a!
[p1, had been fulfilled:
(1) Diameter. "Cystic" bone radiolucency diameter of  10 mm
in large joints, that is, shoulders, hips or knees and a diameter
of  5 mm in any of the small joints of the hands.
(2) Localization. No localization of the "cystic" bone radiolu-
cencies in typical "synovial inclusion" areas, such as the upper
third of femoral neck or the anatomical humeral neck. No
localization of the "cystic" bone radiolucencies in weight bearing
areas of the joint or adjacent to a joint space with degenerative,
osteoarthritic changes.
Using the above criteria, patients were considered to have
radiological evidence of A2m amyloidosis if significant "cystic"
radiolucencies were detected in either  2 different joint regions
or if  2 significant lesions were detected in the bones of one
hand.
Laboratoiy data. In all patients at the time of the study we
determined the plasma levels of parathyroid hormone (PTH). In
both groups, PTH was measured as intact hormone (immunora-
diometric assay; normal range 1.2 to 6.0 pmo!/liter; Allegro,
Heidelberg, Germany). Serum levels of aluminum were deter-
mined in both groups using atomic adsorption spectrometry
and 132-microglobulin concentrations using a radioimmunoassay
(Pharmacia, Mainz, Germany). We also recorded the average
hemoglobin, serum ferritin, total protein and albumin concentra-
tion, using one randomly selected value per year and the mean
serum creatinine, urea, and bicarbonate concentration, using one
randomly selected value per month obtained after a three-day
dialysis interval. Finally, we obtained data on the mean weight, the
duration of each hemodialysis session and the total duration of
erythropoietin therapy.
Hemodialysis data. In all patients, the time spent on home
hemodialysis versus center hemodialysis as well as times spent
with a functioning renal transplant were recorded. All patients
had been dialyzed with different hemodialyzers over time. To
assess the influence of the dialyzers on the prevalence of A132m
amyloidosis, times spent on the various dialyzers were recorded
and classified in one of three groups: (1) dialyzers with cellulose-
based, 7-microglobu1in impermeable membranes (that is, Cu-
prophane); (2) low flux dialyzers with synthetic membranes,
which were either impermeable for 32-microglohulin or had a
2-microg1obuIin sieving coefficient of < 0.1 (dialyzers employed:
low flux polysuiphone and polymethylmethacrylate); (3) high flux
dialyzers with synthetic membranes, which had a 2-microglobulin
sieving coefficient of> 0.1 (dialyzers employed included high flux
acrylonitrile, polyamide and polysuiphone hemodialyzers). In
addition to the dialyzer, we recorded retrospectively the times
spent with different types of dialysate water preparation (that is,
water softener treatment or demineralization vs. reverse osmosis)
and with different types of dialysate buffers (that is, acetate vs.
bicarbonate).
Statistical analysis
All values are expressed as mean SD. Statistical significance
(defined as P < 0.05) was calculated using the t-test for paired
samples, McNemar-test, marginal homogeneity test, chi square
test, Wilcoxon matched pairs signed rank test and Mann-Whitney
U-test where appropriate (and as indicated in the legends to the
tables).
RESULTS
Using the above match criteria, a total of 43 patient pairs was
recruited for this study. The 1988 group was aged 50.9 12.3
years and had been treated with chronic hemodialysis for 71.2
49.4 months, while the 1996 group was aged 50.7 12.5 years and
had been treated for 71.0 49.7 months (Table 1). Two patients
of the 1988 group were studied again in 1996 (with different match
partners). To ascertain that these two patients and their match-
partners did not in any way introduce statistical bias in the results,
we also calculated all following data after omission of the 1996
time point, that is, the two patient pairs were excluded. This
re-analysis did not qualitatively alter any of the results or statis-
tical significances described below (data not shown).
Prevalence of carpal tunnel syndrome
In the 1996 group a 72-year-old woman with diabetic nephrop-
athy had developed a bilateral carpal tunnel syndrome within two
years after the start of hemodialysis. In this case, the unusually
early occurrence of carpal tunnel syndrome [4, 5] was considered
to be related to the diabetes mellitus [111 and was therefore
ignored in the evaluation.
In the 1988 group, carpal tunnel syndrome considered to be
related to chronic hemodialysis treatment had developed in 7 out
of 43 patients while it was present in only 1 out of 43 patients of
the 1996 group. This difference did reach statistical significance
(McNemar test, P < 0.001). Carpal tunnel was bilateral in three of
seven patients of the 1988 group, while it was unilateral in the
single patient of the 1996 group. None of the patients with carpal
tunnel syndrome suffered from any diseases known to be associ-
ated with an increased prevalence of the syndrome, for example
multiple myeloma, rheumatoid arthritis, diabetes mellitus, con-
nective tissue disorders, myxedema, acromegaly, local trauma or
infection [11].
Prevalence of radiological signs indicative of A2m amyloidosis
X-ray images were unavailable in 2 patients of the 1988 group
and 7 patients of the 1996 group, so that 34 patient pairs could
eventually be included in the evaluation. Radiological evidence of
A132m amyloidosis using the modified criteria of van Ypersele et
al [91 (see above) was present in 13 of 34 patients of the 1988
group and in 3 of 34 patients of the 1996 group (McNemar test,
P < 0.001). In order to assess the extent of radiological changes in
the patients, we also counted the number of regions (hands,
shoulders, hips and knees, that is, 8 per patients) showing
significant "cystic" changes in those patients who were considered
to show radiological evidence of Af32m amyloidosis. In this latter
evaluation, 33 of 272 regions showed "cystic" changes in the 1988
group versus 7 of 272 regions in the 1996 group (P < 0.05).
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Table 1. Clinical data of the 1988 and 1996 patient groups
Variable 1988 Group (N = 43) 1996 Group (N 43) P
Age years 51 12 (26—80) 51 13 (22—75) NS"
Sex male.fèmale 37:6 32:11 NSd
Weight kg 68 14 (35—111) 70 13 (45—101) NS"
Time on HD months 71 49 (3—204) 71 50 (4—207) NSC
Duration of HD session hr 5.1 0.7 (3.5—7.4) 4.8 0.5 (3.4—5.8) 0.006"
Number of transplanted patients 9 10 NSd
Time with functioning renal transplant months 6.8 22.7 (1—121) 8.1 31.8 (1—200) NS"
Underlying renal disease
glomerulonephritis' 12 19
interstitial nephropathy 12 5
polycystic disease 7 6 NS1
diabetes mellitus 1 3
hypertensive damage 6 6
various' 5 4
Residual diuresis
<100 ml/day 22 25
100-500 mI/day 9 8 NS1
500-1000 mI/day 3 8
>1000 mI/day 2
unknown 7 0
N of patients receiving erythropoietin therapy 5 37 <0.0O1j
N of parathyroidectomies 5 1 NSd
Data are means so (range) or absolute frequencies. N is number.
"Primary glomerulonephritis or secondary glomerulonephritis due to vasculitides
' AA-amyloidosis, oxalosis, unknown, retroperitoneal fibrosis
Calculated using the paired t test
d Calculated using the McNemar-test
"Calculated using the Wilcoxon matched-pairs signed rank test
Calculated using the marginal homogeneity test
Table 2. Laboratory data of the 1988 and 1996 patient groups
Variable 1988 Group Range 1996 Group Range N P"
Intact PTHpmoI/liter 27 31 (3—130) 19 22 (1—108) 28 NS
Serum aluminum pg/liter 53 35 (5—193) 31 26 (5—134) 37 <0.001
Serum 32-microglobulin mg/liter 41 7 (30—63) 44 17 (23—92) 30 NS
Hemoglobin g/dl 9.8 1.7 (6.5—13.3) 10.0 0.9 (8—12.3) 43 NS
Serum ferritin pg/liter 267 259 (14—795) 242 193 (11—859) 40 NS
Serum total protein g/liter 67 7 (4 1—79) 68 6 (43—80) 43 NS
Serum albumin glliter 44 7 (24—51) 43 3 (18—49) 33 NS
Serum creatinine p.mol/liter 1069 230 (461—1469) 961 192 (513—1318) 43 0.02
Serum urea mmol/liter 26 4 (14—33) 27 13 (15—109) 43 NS
Serum bicarbonate mmol/liter 20 2 (15—25) 20 4 (14—37) 26 NS
Data are means SD (range) or absolute frequencies. "N" denotes the number of patient pairs from whom sufficient data could be obtained.
Calculated using Wilcoxon matched-pairs signed rank test
Comparison of clinical data of the 1988 group versus the 1996 the 1996 group, while no significant differences evolved for serum
group 32-microglobuIin levels, intact PTH, hemoglobin, ferritin, total
As shown in Table 1, the two groups of patients did not show protein, albumin, urea, and bicarbonate concentrations.
significant differences with respect to age (a match criterion), sex,
weight, total time on hemodialysis (the second match criterion), Comparison of hemodialysis data of the 1988 group versus the
number of patients with renal transplants and times with fune- 1996 group
tioning transplants, underlying renal diseases, residual diuresis
and the number of parathyroidectomies. The lengths of hemodi- Table 3 and Figures 1 and 2 demonstrate that significant
alysis sessions was significantly longer in the 1988 patients as differences existed between the two groups with respect to various
compared to the 1996 group and usage of erythropoietin was hemodialysis related parameters: number of patients on (Table 3,
significantly more frequent in the 1996 group (Table 1). top) and duration (Table 3, bottom) treated with home versus
center hemodialysis, times spent on hemodialysis with the various
Comparison of laboratory data of the 1988 group versus the
membranes, dialysate water preparations and clialysate buffers.
1996 group Treatments with high-flux hemodialysis membranes were qualita-
Table 2 shows that aluminium and creatinine serum eoncentra- tively comparable in both groups: More than 90% of the treat-
tions were significantly higher in the 1988 patients as compared to ments were performed using high flux polysulphone or polyamicle
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Table 3. Hemodialysis data of the 1988 and 1996 patient groups
Variable 1988 N 1996 N Pa
No. of patients on
Home HD 23 6 <0.001
Center HD 30 41 NS
No. of patients using hemodialyzers
Cellulose based 40 33 NS
Low flux synthetic 12 34 <0.001
High flux synthetic 11 25 0.004
No. of patients using dialysate water preparation
Demineralization/water softener 17 4 0.002
Reverse osmosis 43 43 NS
No. of patients using dialysate buffer
Acetate 29 8 <0.001
Bicarbonate 29 43 NS
Variable 1988 Group 1996 Group pb
Home HD months 75 53 (2—192) 74 40 (33—137) NS
Center HD months 44 32 (3—152) 64 40 (4—181) 0.04
Hemodialyzers used months
Cellulose based 50 46 (1—204) 45 45 (1—176) NS
Low flux synthetic 31 28 (1—84) 22 24 (1—120) NS
High flux synthetic 11 6 (3—24) 18 18 (1—70) NS
Dialysate water preparation months
Demineralization/water softener 52 46 (2—153) 39 29 (2—72) NS
Reverse osmosis 51 26 (3—152) 67 43 (4—181) NS
Dialysate buffer months
Acetate 68 54 (1—180) 59 46 (2—108) NS
Bicarbonate 27 19 (2—60) 60 32 (4—138) <0.001
Data are presented as numbers of patients receiving specific treatments (some patients were switched between different treatments) (Top) and the
length of time (mean SD; range) (Bottom) for which these patients received each specific treatment modality (note that the times given in the bottom
part only refer to the number of patients shown in the top part and not the total number of patients).
a Analyzed using the chi square test (Fishers exact test)bAnalyzed using the Mann-Whitney U test
membranes membranes
Fig. 1. Comparison of the relative times (expressed as percentage of total
HD time) that the patients received hemodialysis with either of the
dialyzer membrane categories. For the purposes of this figure, all patients
of the 1988 () and 1996 (•) group were included. Those patients, who
had not received a particular treatment, were counted as zero months.
membranes and < 10% of the treatments were performed with
high-flux acrylonitrile membranes.
Comparison of Aj32m amyloid positive patients with negative
patients
Sixteen patients were identified as showing manifestations of
A/32m amyloidosis (carpal tunnel syndrome, X-ray findings) in the
1988 group as opposed to 4 patients in the 1996 group (McNemar
DISCUSSION
The data of the present study demonstrate that the prevalence
of A/32m amyloidosis in our center, as judged by clinical and
radiological signs, has decreased dramatically between the evalu-
ation in 1988 and that in 1996. Also, the individual extent of
amyloid deposition in those few 1996 patients, who showed signs
of the amyloidosis, had decreased.
It has frequently been speculated that by increasing /32-micro-
globulin removal during treatment, the development of A/32m
amyloidosis should at least be delayed [9, 12]. In fact, some (but
not all) currently available studies appear to support this assump-
tion [9, 13—16]. Intradialytic /32-microglobulin removal can be
increased by the usage of high flux synthetic membranes, by
increasing convective transport, and, possibly, by the usage of
132-microglobulin adsorbing devices [12, 17—19]. However, be-
tween 1988 and 1996 we have made no systematic attempt to
increase 2-microglobulin removal and none of our patients had
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NS test: P 0.002).Table 4 shows the comparison of some charac-
teristics of the amyloid positive versus negative patients per group.
Albeit not statistically significant, it is noteworthy that the four
patients of the 1996 group with signs of amyloidosis had been on
hemodialysis for a longer time than the positive patients of 1988
(136 65 months vs. 86 57 months; P 0,13). Apart from the
characteristics depicted in Table 4, no significant differences were
noted between amyloid "positive" and "negative" patients of both
groups for any of the other parameters described in Tables 1 to 3
(data not shown).HD with HD with HD with Unknown
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Table 4. Characteristics of patients with signs of A132m amyloidosis "Positive" as opposed to those without "Negative" in the 1988 patient group and
the 1996 patient group
1988 group 1996 Group
Positive (N = 16) N Negative (N = 18) N Positive (N = 4) N Negative (N = 30) N
Ageyeors 57±8 16 49±12 18 55±4 4 52±12 30
Total time on HDmonths 86 57 16 57 45 18 136 65 4 62 45a 30
TimeonhomeHDmonths 98±59 9 71±54 8 86±50 3 62±32 3
Time on center HD months 45 24 11 33 27 14 95 51 3 58 37 29
Hemodialyzers used months
Cellulose based 67 53 14 37 38 17 105 56 4 35 29 21
Low flux synthetic 37 29 5 27±31 6 23 25 3 22 25 28
Highfluxsynthetic 9±5 8 16 1 6,13 2 17±18 16
Dialysate water preparation months
Demineralization/water softener 80 43 7 39 45 7 28 23 3 72 1
Reverse osmosis 51 20 16 42 24 18 115 48 4 60 39 30
Dialysate buffer months
Acetate 86±56 11 52±52 11 74±30 3 35±50 4
Bicarbonate 29±15 13 26±22 12 81±36 4 57±35 30
Data are means SD.
aP < 0.05 versus positive patients of the same group (calculated using Mann-Whitney U test)
been switched to treatment with hemofiltration, hemodiafiltration
or J32-microglobulin adsorbing devices. Nevertheless, inspection
of Table 3 shows that the usage of high flux synthetic membranes
for hemodialysis has indeed increased significantly in our center
between the 1980s and 1990s. It seems highly unlikely that this
change is responsible for the observed decrease in A132m amy-
loidosis prevalence. First, although within the 1996 patient group
significantly more patients had received hemodialysis with high-
flux synthetic membranes, the relative overall contribution of high
flux treatment to the total duration of hemodialysis only increased
from 6% in 1988 to 13% in 1996 (Fig. 1). Second, the 1988
patients with evidence of the amyloidosis did not represent a
negative selection, that is, a group of patients who had exclusively
been dialyzed with p2-microglobulin impermeable membranes
(Table 4). Finally, serum levels of /32-microglobulin did not differ
significantly between the two groups.
If an increase in intradialytic f32-microglobulin is unlikely to
account for the decreased amyloidosis prevalence, what other
factors may have contributed to this phenomenon? The only
established factors that govern the amyloidosis manifestation,
namely age of the patients and total time on hemodialysis [1, 2, 9],
are excluded since our patients were matched for both. Based on
our data, four alternative factors warrant consideration: (1) the
decrease in aluminum exposure between 1988 and 1996; (2) usage
of erythropoietin, need for transfusions and consecutive iron
overload. While it has been speculated that both aluminum and
iron may play a role in the Af32m amyloid pathogenesis [20, 21],
no significant evidence to support such speculation is presently
available. Furthermore, it is noteworthy that neither mean hemo-
globin levels nor serum ferritin levels were different between the
two patient groups (Table 2). (3) In "underdialysis" it is conceiv-
able, though completely speculative, that the uremic milieu con-
tributes to the amyloidogenesis. In this respect it is important to
note that neither the average predialysis serum urea nor serum
albumin levels differed between the 1988 and 1996 group (Table
2), which essentially excludes that major differences of the dialysis
doses delivered had existed between the two groups. We therefore
believe that the most attractive possibility is that (4) changes in
P<0.01 P<0.001
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or softened HD water
Fig. 2. Comparison of the relative times (expressed as percentage of total HD time) that the patients received home or center HD, hemodialysis with
either of the water treatment modalities or with either of the dialysate buffers. For the purposes of this figure, all patients of the 1988 () and 1996
(•) group were inctuded. Those patients who had not received a particular treatment were counted as zero months.
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dialysis treatment other than 2-microglobulin removal accounted
for the decreasing prevalence of the amyloidosis.
We and others have repeatedly speculated that factors related
to the so-called "biocompatibility" of the hemodialysis circuit as
well as dialysate related factors may contribute to the pathogen-
esis of Af32m amyloidosis [18, 22, 23]. Such factors include the
dialyzer induced generation of inflammatory mediators, protease
activation, oxygen radical release, etc., as well as the dialysate
buffer and microbiological purity of the dialysate [18, 22, 23]. On
a theoretical basis, multiple ways are conceivable, by which these
factors could affect the amyloidogenesis [18, 22, 23]. With respect
to changes of the hemodialysis membranes between the 1988 and
1996 group, a highly significant increase in the usage of so-called
"biocompatible" synthetic membranes was in fact noted (Table 3).
Since both low and high flux synthetic membranes in comparison
to cellulose based membranes generate less inflammatory medi-
ators, induce less release of proteases, etc., this could have
affected the A2m prevalence independent of the /32-microglobu-
tin removal issue. However, again it has to be stressed that the
increase in synthetic membrane hemodialyzer usage, albeit highly
significant, is small on a relative base, that is, it increased from
18% to 42% (Fig. 1) of the total hemodialysis time.
Based on the above considerations, we suggest that the most
likely factor(s) accounting for the marked decrease of A/32m
amyloid prevalence in our center are changes of the dialysate
composition and purity that have occurred between the 1980s and
1990s. Table 3 shows that the usage of acetate buffered dialysate
markedly decreased between the two study periods. Also, the
dialysate water preparation underwent considerable changes,
since water treated by demineralization or water softeners had
been used for the dialysate preparation in most home hemodial-
ysis patients of the 1988 group, while almost all patients of the
1996 group were using reverse osmosis water. Unpublished data
from our own center as well as data from the literature [24—26]
suggest that home hemodialysis together with the usage of water
softener treated or demineralized water results in a significantly
higher number of colony forming units per liter of dialysate and
significantly more fever episodes than does center hemodialysis
with reverse osmosis water. Both the usage of acetate dialysate as
well as microbiological contamination, in particular endotoxin
contamination, of the dialysate have been shown to induce
systemic inflammatory responses during hemodialysis [27—29]. In
the past it has remained speculative, whether such induction of
inflammatory reactions has any clinical consequences and we were
left to speculate on the possible links to A2rn amyloidosis [18, 22,
23]. Interestingly, Baz et al reported in 1991 that a change from
regular dialysate to ultrapure dialysate significantly delayed the
occurrence of new cases with carpal tunnel syndrome, despite the
continued usage of cellulose based membranes [30].
In conclusion, we have observed a considerable decrease of
Af3,m amyloid manifestations in our dialysis center between an
evaluation in 1988 and in 1996. This decrease is most likely
explained by changes in dialysate composition and in particular
purity, although we cannot exclude influences of additional fac-
tors, such as the so-called "biocompatibility" of hemodialyzers,
aluminium or erythropoietin therapy. At present renal transplan-
tation is the only way to either completely prevent the develop-
mentor at least halt the progression of A2m amyloidosis [31, 32].
The findings of the present study therefore appear of importance
since they suggest that non-transplant factors such as dialysate
purity can also lead to a decreased manifestation of the amyloid-
osis. This observation is particularly relevant for those countries,
where transplantation is not readily available, and for those
patients who cannot receive a renal transplant.
ACKNOWLEDGMENTS
The authors thank Dr. TOrök, Department of Statistics, Hannover
Medical School for valuable advice in the evaluation of the study.
Reprint requests to Jurgen Floege, M.D., Division of Nephrology 6840,
Medizinische Hochschule, 30623 Hannover, Germany.
REFERENCES
1. KOCH KM: Dialysis-related amyloidosis. Kidney mt 41:1416—1429,
1992
2. FLOEGE J, EHLERDING G: Beta-2-microglobulin associated amyloid-
osis. Nephron 72:9—26, 1996
3. SCHWARZ A, KELLER F, SEYFERT S, POLL W, MOLZAHN M, DISTLER
A: Carpal tunnel syndrome: A major complication in long term
hemodialysis patients. Clin Nephrol 22:133—137, 1984
4. GEJYO F, HOMMA N, ARAKAWA M: Carpal tunnel syndrome and
beta-2-microglobulio related amyloidosis in chronic hemodialysis pa-
tients. Blood Purif6:t25—131, 1988
5. CHARRA B, CALEMARD E, LAURENT G: Chronic renal failure treat-
ment duration and mode: Their relevance to the late dialysis periar-
ticular syndrome. Blood Purif6:117—124, 1988
6. FLOEGE J, BURCHERT W, BRANDIS A, GIELOW P, NONNAST DANIEL B,
SPINDLER E, HUNDESHAGEN H, SHALDON S, Kocu KM: Imaging of
dialysis-related amyloid (AB-amyloid) deposits with [131]I-beta-2-
microglobulin. Kidney mt 38:1169—1176, 1990
7. YPERSELE DE STRIHOU C, FLOEGE J, JADOUL M, Kocu KM: Amyloid-
osis and its relationship to different dialysers. Nephrol Dial Transplant
9:156—161, 1994
8. FLOEGE J, KOCH KM: Beta-2-mieroglobulin associated amyloidosis
and therapy with high flux hemodialysis membranes. Clin Nephrol
42(Suppl 1):552—556, 1994
9. VAN YPERSELE DE STRIHOU C, JADOUL M, MALGHEM J, MALDAGUE B,
JAMART J, AMYLOIDOSIS WORKING PARTY ON DIALYSIS: Effect of
dialysis membrane and patients age on signs of dialysis-related
amyloidosis. Kidney mt 38:10t2—1019, 1990
10. TEKINSOY B, NONNAST-DANIEL B, SCHAEFER J, REICHELT S, PROKOP
M, GALANSKI M: Destructive non-infectious spondylarthropathy dur-
ing hemodialysis. Aktuelle Radiologie 1:65—69, 1991
11. DORWART BB: Carpal tunnel syndrome: A review. Semin Arthritis
Rheum 14:134—140, 1984
12. FLOEGE J, SMEBY LC: High flux membranes and dialysis related
amyloidosis. Contrib Nephrol 96:124—137, 1991
13. CHANARD J, BINDI P, LAvAUD S, TOUPANCE 0, MAHEUT H, LACOUR
F: Carpal tunnel syndrome and type of dialysis membrane. Br Med J
298:867—868, 1989
14. BRUNNER FP, BRYNGER H, EHRICI-I JHH, FASSBINDER W, GEERLINGS
W, Rzzor'o G, SELWOOD NH, TUFVESON G, WING AJ: Case control
study on dialysis arthropathy: The influence of two different dialysis
membranes: Data from the EDTA registry. Nephrol Dial Transplant
5:432—436, 1990
IS. KESSI,ER M, NETTER P, MAHEUT II, WOLF C, PRENAT E, CAO Hrni T,
GAUCHER A: highly permeable and hiocompatible membranes and
prevalences of dialysis-associated arthropathy. Lance! 337:1092—1093,
1991
16. MIURA Y, ISHIYANA T, INOMATA A, TAKEDA T, SENMA S, OKUYAMA
K, SUZUKI Y: Radiolucent bone cysts and the type of dialysis
membrane used in patients undergoing long-term hemodialysis.
IVephron 60:268—273, 1992
17. FI.OGE J, GRANOLLERAS C, BINGLE M, DESCHODT G, BRANGER B,
OULES R, KOCH KJvI, SHALDON 5: Beta-2-microglohulin kinetics
during hacmodialysis and haemofiltration. Nephrol Dial Transplant
1:223—228, 1987
18. ZENGRAFF J, DRUEKE T: Can the nephrologist prevent dialysis-related
amyloidosis?Am JKid Dis 18:1—11, 1991
19. II0MMA N, GEJYG F, HASEGAWA S, TERAMURA T, El I, MARLYAMA H,
ARAKAWA M: Effects of a new adsorbent column for removing
Schwalbe et al: f3,-microglobulin associated amyloidosis 1083
beta-2-microglobulin from circulating blood of dialysis patients. Con-
trib Nephrol 112:164—171, 1995
20. CARY NR, SETH! D, BROWN EA, ERHARDT CC, WooDRow DF,
GOWER PE: Dialysis arthropathy: Amyloid or iron? Br Med J 293:
1392—1394, 1986
21. BARDIN T, KUNTZ D: The arthropathy of chronic haemodialysis. Clin
Exp Rheumatol 5:379—386, 1987
22. FLOEGE J, SCHAFFER J, KOCH KM, SHALDON S: Dialysis related
amyloidosis: A disease of chronic retention and inflammation? Kidney
mt 42(Suppl):578—S85, 1992
23. RITZ E, BOMMER J: Beta-2-microglobulin-derived amyloid—Problems
and perspectives. Blood Punf 6:61—68, 1988
24. Do M0uLIN GC, COLEMAN EC, HEDLEY-WIIYTE J: Bacterial coloni-
zation and endotoxin content of a new renal dialysis water system
composed of acrylonitrile hutadiene styrene. Appi Environ Microbiol
53:1322—1326, 1987
25. LAUER J, STREIFEL A, KJELLSTRAND C, DEROOS R: The bacteriolog-
ical quality of hemodialysis solution as related to several environmen-
tal factors. Nephron 15:87—97, 1975
26. FAVERO MS, PETERSEN NJ, BOYER KM, CARSON LA, BOND WW:
Microbial contamination of renal dialysis systems and associated
health risks. Trans ASAJO 20:175—183, 1974
27. BINGEL M, LONNEMANN G, KOCH KM, DINARELLO CA, SHALDON S:
Enhancement of in vitro human interleukin-1 production by sodium
acetate. Lancet 1:14—16, 1987
28. LONNEMANN G, FLOEGE J, SHALDON S, K0CFI KM: Blood-dialyzer
interactions: Their role in long-term complications of hemodialysis.
Contrib Nephrol 100:155—171, 1992
29. LONNEMANN G: Dialysate bacteriological quality and the permeability
of dialyzcr membranes to pyrogens. Kidney mt 41:S195—S200, 1993
30. BAZ M, DURAND C, RAGON A, JABER K, ANDRIEU D, MERZOUK T,
PURGUS R, OLMER M, REYNIER iF, BERLAND Y: Using ultrapure
water in hemodialysis delays carpal tunnel syndrome. IntfArtif Organs
14:681—685, 1991
31. BARDIN T, LEBAIL DARNE JL, ZINGRAFF J, LAREDO JD, VOISIN MC,
KREIS H, KUNTZ D: Dialysis arthropathy: Outcome after renal trans-
plantation. Am J Med 23:243—248, 1995
32. CAMPISTOL JM, PONZ E, MuNoz GOMEZ J, OPPENHEIMER F, RICARD
MJ, VILARDELL J, ANDREU J: Renal transplantation for dialysis
amyloidosis. Transplant Proc 24:118—119, 1992
